GreenRoc now on the EU radar after presentation on Amitsoq at the Greenland Business Mission. Watch the interview here.

Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Sponsored Content

Pin to quick picksGenincode Regulatory News (GENI)

Share Price Information for Genincode (GENI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.00
Ask: 5.50
Change: 0.00 (0.00%)
Spread: 0.50 (10.00%)
Open: 5.25
High: 5.25
Low: 5.25
Prev. Close: 5.25

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Results

3 May 2022 07:00

RNS Number : 9350J
GENinCode PLC
03 May 2022
 

 

GENinCode Plc

("GENinCode" or the "Company")

 

Notice of results

Analyst & investor presentations

 

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces it will issue its preliminary results for the year ended 31 December 2021 on Tuesday, 17 May 2022.

 

Matthew Walls, CEO, and Paul Foulger, CFO will host an in-person analyst meeting at the offices of Walbrook PR, 75 King William Street, London EC4N 7BE at 9.30am on 17 May. If you would like to attend, please contact Walbrook PR at genincode@walbrookpr.com or on 020 7933 8780.

 

The Company will also host a presentation for investors via the IMC platform at 3pm on 17 May. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. To register for this, please use the following link: https://www.investormeetcompany.com/genincode-plc/register-investor

 

For more information visit www.genincode.com

 

GENinCode Plc

www.genincode.com or via Walbrook PR

Matthew Walls, CEO

Paul Foulger, CFO

Stifel Nicolaus Europe Limited (Nomad and Joint Broker)

Tel: +44 (0)20 7710 7600

Alex Price / Ben Maddison / Richard Short

Cenkos Securities Plc (Joint Broker)

Tel: +44 (0)20 7397 8900

Giles Balleny

Dale Bellis / Michael Johnson (Sales)

Walbrook PR Limited

Tel: 020 7933 8780 or

Anna Dunphy / Paul McManus / Louis Ashe-Jepson

genincode@walbrookpr.com

 

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

 

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

 

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.

About Cardiovascular Disease

Cardiovascular disease (CVD) is the leading cause of death globally, taking an estimated 17.9 million lives each year. CVD is a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age.

 

The most important behavioural risk factors of heart disease and stroke are unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol. The effects of behavioural risk factors may show up in individuals as raised blood pressure, raised blood glucose, raised blood lipids, and overweight and obesity. These "intermediate risks factors" can be measured in primary care facilities and indicate an increased risk of heart attack, stroke, heart failure and other complications.

 

Cessation of tobacco use, reduction of salt in the diet, eating more fruit and vegetables, regular physical activity and avoiding harmful use of alcohol have been shown to reduce the risk of cardiovascular disease. Health policies that create conducive environments for making healthy choices affordable and available are essential for motivating people to adopt and sustain healthy behaviours.

 

Identifying those at highest risk of CVDs and ensuring they receive appropriate treatment can prevent premature deaths. Access to noncommunicable disease medicines and basic health technologies in all primary health care facilities is essential to ensure that those in need receive treatment and counselling.

 

CVD causes a quarter of all deaths in the UK and is the largest cause of premature mortality in deprived areas and is the single biggest area where the NHS can save lives over the next 10 years. CVD is largely preventable, through lifestyle changes and a combination of public health and NHS action on smoking and tobacco addiction, obesity, tackling alcohol misuse and food reformulation.

 

Genetic risk assessment can help early detection and treatment of CVD to help patients live longer, healthier lives. Many people are still living with undetected, high-risk conditions such as high blood pressure, raised cholesterol, and atrial fibrillation (AF). Progress continues in the NHS to identify and diagnose people routinely knowing their 'ABC' (testing and monitoring of AF, Blood pressure and Cholesterol) set out in the NHS 10 Year plan.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORILMATMTMTBJT
12
Date   Source Headline
25th Sep 20247:00 amRNSHalf-year Report
20th Sep 20247:36 amRNSCollaboration with The Family Heart Foundation
9th Sep 20247:00 amRNSNotice of Results
28th Aug 20247:00 amRNSCARDIO inCode-Score presentation
27th Jun 20244:02 pmRNSResult of AGM
5th Jun 20245:17 pmRNSPosting of Annual Report and Notice of AGM
3rd Jun 20247:00 amRNSFinal Results
23rd May 20247:00 amRNSNotice of Results
1st May 20247:00 amRNSCARDIO inCode-Score presentation
26th Apr 20242:30 pmRNSGrant of Options & Surrender of Existing Options
4th Apr 202410:44 amRNSCARDIO inCode-Score® US study publication
21st Mar 202410:58 amRNSNew NICE Guidance for Ovarian Cancer
9th Feb 202410:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSHolding(s) in Company
11th Jan 20242:49 pmRNSHolding(s) in Company
11th Jan 20242:30 pmRNSHolding(s) in Company
9th Jan 20241:30 pmRNSResult of GM and Total Voting Rights
28th Dec 20237:00 amRNSResult of Retail Offer
21st Dec 20236:25 pmRNSResult of Placing and Subscription
21st Dec 20234:59 pmRNSRetail Offer
21st Dec 20234:55 pmRNSPlacing and Subscription
29th Nov 20237:10 amRNSCARDIO inCode-Score 510(k) FDA submission update
29th Nov 20237:00 amRNSChange of Adviser
12th Oct 20237:00 amRNSShareSoc investor presentation
20th Sep 20237:00 amRNSHalf-year Report
13th Sep 20237:00 amRNSNotice of Results
30th Aug 20237:00 amRNSPresentation at European Society of Cardiology
16th Aug 202310:27 amRNSCARDIO inCode 510k filing
19th Jul 20237:00 amRNSCollaboration with US healthcare provider
30th Jun 20234:03 pmRNSResult of AGM
8th Jun 20231:31 pmRNSNotice of AGM and posting of Annual Report
6th Jun 20237:00 amRNSFinal Results
5th Jun 20237:00 amRNSNotice of Results
22nd May 20237:00 amRNSCARDIO inCode be presented at conference
15th May 20237:00 amRNSCollaboration with University Clinic Dresden
2nd May 20237:00 amRNSNHS LIPID inCode testing implementation
3rd Apr 20237:00 amRNSCARDIO InCode CPT PLA Code
13th Mar 20237:00 amRNSStatement re: Silicon Valley Bank
3rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
3rd Jan 20234:35 pmRNSPrice Monitoring Extension
3rd Jan 20237:00 amRNSApproval of California state license
22nd Nov 20222:07 pmRNSIssue of Share Options
3rd Nov 20227:00 amRNSBritish Medical Journal publication
10th Oct 20226:23 pmRNSHolding(s) in Company
27th Sep 20227:00 amRNSHalf-year report
7th Sep 20227:00 amRNSNotice of results
26th Jul 20227:00 amRNSNHS implementation of Lipid inCode testing
23rd Jun 20222:37 pmRNSResult of AGM
23rd May 20224:06 pmRNSPosting of Annual Report and Notice of AGM
17th May 20227:00 amRNSFinal Results
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Track Your Investments

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.